High specific activity radiolanthanides

I&EC 134

Cathy Cutler, cutlerc@missouri.edu1, Hendrik Engelbrecht1, Michael R. Lewis, lewismic@missouri.edu2, Carolyn J. Anderson, andersoncj@mir.wustl.edu3, Timothy J. Hoffman, HoffmanT@health.missouri.edu4, and Alan R. Ketring, ketringa@missouri.edu5. (1) Research Reactor, University of Missouri, Research Park, Columbia, MO 65211, (2) Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, Columbia, MO 65211, (3) Division of Radiological Sciences, Washington University School of Medicine, St. Louis, MO 63110, (4) Division of Hematology & Medical Oncology, Ellis Fischel Cancer Center, University of Missouri, Harry S. Truman Memorial Veterans' Hospital, 800 Hospital Drive - Research, Columbia, MO 65201, (5) University of Missouri, Research Park, Columbia, MO 65211
Production of radioactive lanthanides is of interest for their use in diagnosis and therapy. Recent research has focused on developing high specific radiolanthanides which can be attached to biomolecules that are selectively targeted to diseased tissues, thus delivering the radioactivity to the diseased tissue while minimizing or sparing damage to healthy or normal tissue. Low concentrations of tumor-associated antigens require that biomolecules be radiolabeled with high specific radionuclides. Indirect production methods have been developed for producing high specific activity radiolanthanides such as Lu-177, Pm-149, and Ho-166. For example, neutron irradiation of Nd-148 produces Nd-149 (half-life = 1.7 hr), which is followed by beta decay, producing Pm-149. In all cases it is critical to separate the picogram quantities of high specific activity radiolanthanide produced from the milligram quantities of the target material. The production and evaluation of these high specific radiolanthanides attached to targeting biomolecules will be presented.